Современные аспекты в диагностике и лечении адренокортикального рака
Вопросы онкологии
Дата публикации: декабря 10, 2014
Ключевые слова
адренокортикальный рак
митотан
сунитиниб
сорафениб
митотан
сунитиниб
сорафениб
Как цитировать
Филимонюк А., Тедорадзе Р., Шарнов М., Антонов А., Лунев С., Чечеткин С. Современные аспекты в диагностике и лечении адренокортикального рака // Кремлевская медицина. Клинический вестник. 2014. Т. № 4. С. 86-90.
Аннотация
Адренокортикальный рак (АКР) — редкое злокачественное образование, для которого до сих пор не разработа-ны однозначные критерии диагностики и методы лечения. В данной статье проведен анализ собственного и мировогоопыта, суммированы имеющиеся стандарты. Пациентам, у которых подозревается АКР, следует проводить тщательноеисследование гормонального статуса, а также широко применять различные методы визуализации. Радикальное уда-ление образования должно проводиться даже при наличии местнораспространенных форм заболевания, после чегов адъювантном режиме рекомендуется применение митотана; когда опухоль считается неоперабельной, к митотануследует добавить и другие химиотерапевтические препараты. В разработке находятся и несколько новых таргетныхпрепаратов, например ингибиторы IGF-1, сунитиниб, сорафениб. Лучевая терапия является методом выбора при мета-стазах в кости и головной мозг.Ключевые слова: адренокортикальный рак, митотан, сунитиниб, сорафениб.Adrenocortical cancer (ACC) is a rare malignant disease for diagnostics and treatment of which no univocal criteria havebeen developed yet. The given article presents world and authors’ own experience; it also discusses and summarizes existingstandards. If a patient is suspected of adrenocortical cancer a thorough examination of his hormonal status and various visualtechniques for diagnostics should be widely applied. Radical tumor removal has to be done even in locally invasive forms; afterthat Mitotan is recommended in an adjuvant regime. If the tumor is considered inoperable, Mitotan should be added with otherchemiotherapeutic preparations. Currently, some new target preparation are being developed; for example, inhibitors IGF-1,preparations Sunitinib, Sorafenib. Radial therapy is a method of choice in case of metastases into bones and brain.Кey words: adrenocortical cancer, Mitotan, Sunitinib, Sorafenib.Литература
1. Abiven G., Coste J., Groussin L. et al. Clinical and biological
features in the prognosis of adrenocortical cancer: pooroutcome of
cortisol-secreting tumors in a series of 202 consecutive patients. The
Journal of 2. Clinical Endocrinology and Metabolism. – 2006. –
Vol. 91. – P. 2650–2655.
3. Almeida M.Q., Fragoso M.C., Lotfi C.F. et al. Expression of
IGF-II and its receptor in pediatric and adult adrenocortical tumors.
The Journal of Clinical Endocrinology and Metabolism. – 2008.
Sep; 93 (9). – P. 3524–3531.
4. Assie G., Antoni G., Tissier F. et al. Prognostic parameters
of metastatic adrenocortical carcinoma. The Journal of Clinical
Endocrinology and Metabolism – 2007. – Vol. 92. – P. 148–154.
5. Berruti A., Terzolo M., Sperone P. et al. Etoposide,
doxorubicin and cisplatin plus mitotane in the treatment of advanced
adrenocortical carcinoma: a large prospective phase II trial. Endocr
Relat Cancer. – 2005. – Vol. 12. – P. 657–666.
6. Bovio S., Cataldi A., Reimondo G. et al. Prevalence of
adrenal incidentaloma in a contemporary computerized tomography
series. Journal of Endocrinological Investigation. – 2006. – Vol. 29.
– P. 298–302.
7. Fassnacht M., Johanssen S., Quinkler M. et al. Limited
prognostic value of the 2004 UICC staging classification for
adrenocortical carcinoma - proposal for a revised TNM classification.
Cancer. – 2009, Jan 15. – Vol. 115 (2). – P. 243–250.
8. Han S.J., Kim T.S., Jeon S.W. et al. Analysis of adrenal
masses by 18F-FDG positron emission tomography scanning.
International Journal of Clinical Practice. – 2007. – Vol. 61. – P.
802–809.
9. Ilias I., Sahdev A., Reznek R.H. et al. The optimal imaging
of adrenal tumours: a comparison of different methods. EndocrRelat
Cancer. – 2007. – Vol. 14. – P. 587–599.
10. Kebebew E., Reiff E., Duh Q.Y. et al. Extent of disease at
presentation and outcome for adrenocortical carcinoma: have we
made progress? World Journal of Surgery. – 2006. – Vol. 30. – P.
872–878.
11. Kirschner L.S. Emerging treatment strategies for
adrenocortical carcinoma: a new hope. The Journal of Clinical
Endocrinology and Metabolism. – 2006. – Vol. 91. – P. 14–21.
12. Libe R., Fratticci A. & Bertherat J. Adrenocortical cancer:
pathophysiology and clinical management. Endocr Relat Cancer. –
2007. – Vol. 14. – P. 13–28.
13. Mansmann G., Lau J., Balk E. et al. The clinically
inapparent adrenal mass: update in diagnosis and management.
Endocrine Reviews. – 2004. –Vol. 25. – P. 309–340.
14. Morimoto R., Satoh F., Murakami O. et al.
Immunohistochemistry of a proliferation marker Ki67/MIB1 in
adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor
for recurrence of adrenocortical carcinomas. Endocrine Journal. –
2008. – Vol. 55. – P. 49–55.
15. Park B.K., Kim C.K., Kim B. et al. Comparison of delayed
enhanced CT and chemical shift MR for evaluating hyperattenuating
incidental adrenal masses. Radiology. – 2007. – Vol. 243. – P.
760–765.
16. Samnotra V., Vassilopoulou-Sellin R & Fojo AT. A phase
II trial of gefitinib monotherapy in patients with unresectable
adrenocortical carcinoma (ACC). Proceedings of the Annual
Meeting of the American Society of Clinical Oncology. – 2007
[abstract no 15527].
17. Sasano H., Suzuki T. & Moriya T. Recent advances
in histopathology and immunohistochemistry of adrenocortical
carcinoma. Endocrine Pathology. – 2006. – Vol. 17. – P. 345–354.
18. Schlamp A., Hallfeldt K., Mueller-Lisse U. et al. Recurrent
adrenocortical carcinoma after laparoscopic resection. Nature
Clinical Practice, Endocrinology & Metabolism. – 2007. – Vol. 3.
– P. 191–195. quiz 1 p following 195.
19. Schteingart D.E., Doherty G.M., Gauger P.G. et al.
Management of patients with adrenal cancer: recommendations
of an international consensus conference. Endocr Relat Cancer. –
2005. – Vol. 12. – P. 667–680.
20. Song J.H., Chaudhry F.S. & Mayo-Smith W.W. The
incidental adrenal mass on CT: prevalence of adrenal disease
in 1,049 consecutive adrenal masses in patients with no known
malignancy. AJR American Journal of Roentgenology. – 2008. –
Vol. 190. – P. 1163–1168.
21. Terzolo M., Angeli A., Fassnacht M. et al. Adjuvant mitotane
treatment in patients with adrenocortical carcinoma. The New
England Journal of Medicine. – 2007. – Vol. 356. – P. 372–380.
22. Quinkler M., Hahner S., Wortmann S. et al. Treatment of
advanced adrenocortical carcinoma with erlotinib plus gemcitabine.
The Journal of Clinical Endocrinology and Metabolism. – 2008. –
Vol. 93. – P. 2057–2062.
features in the prognosis of adrenocortical cancer: pooroutcome of
cortisol-secreting tumors in a series of 202 consecutive patients. The
Journal of 2. Clinical Endocrinology and Metabolism. – 2006. –
Vol. 91. – P. 2650–2655.
3. Almeida M.Q., Fragoso M.C., Lotfi C.F. et al. Expression of
IGF-II and its receptor in pediatric and adult adrenocortical tumors.
The Journal of Clinical Endocrinology and Metabolism. – 2008.
Sep; 93 (9). – P. 3524–3531.
4. Assie G., Antoni G., Tissier F. et al. Prognostic parameters
of metastatic adrenocortical carcinoma. The Journal of Clinical
Endocrinology and Metabolism – 2007. – Vol. 92. – P. 148–154.
5. Berruti A., Terzolo M., Sperone P. et al. Etoposide,
doxorubicin and cisplatin plus mitotane in the treatment of advanced
adrenocortical carcinoma: a large prospective phase II trial. Endocr
Relat Cancer. – 2005. – Vol. 12. – P. 657–666.
6. Bovio S., Cataldi A., Reimondo G. et al. Prevalence of
adrenal incidentaloma in a contemporary computerized tomography
series. Journal of Endocrinological Investigation. – 2006. – Vol. 29.
– P. 298–302.
7. Fassnacht M., Johanssen S., Quinkler M. et al. Limited
prognostic value of the 2004 UICC staging classification for
adrenocortical carcinoma - proposal for a revised TNM classification.
Cancer. – 2009, Jan 15. – Vol. 115 (2). – P. 243–250.
8. Han S.J., Kim T.S., Jeon S.W. et al. Analysis of adrenal
masses by 18F-FDG positron emission tomography scanning.
International Journal of Clinical Practice. – 2007. – Vol. 61. – P.
802–809.
9. Ilias I., Sahdev A., Reznek R.H. et al. The optimal imaging
of adrenal tumours: a comparison of different methods. EndocrRelat
Cancer. – 2007. – Vol. 14. – P. 587–599.
10. Kebebew E., Reiff E., Duh Q.Y. et al. Extent of disease at
presentation and outcome for adrenocortical carcinoma: have we
made progress? World Journal of Surgery. – 2006. – Vol. 30. – P.
872–878.
11. Kirschner L.S. Emerging treatment strategies for
adrenocortical carcinoma: a new hope. The Journal of Clinical
Endocrinology and Metabolism. – 2006. – Vol. 91. – P. 14–21.
12. Libe R., Fratticci A. & Bertherat J. Adrenocortical cancer:
pathophysiology and clinical management. Endocr Relat Cancer. –
2007. – Vol. 14. – P. 13–28.
13. Mansmann G., Lau J., Balk E. et al. The clinically
inapparent adrenal mass: update in diagnosis and management.
Endocrine Reviews. – 2004. –Vol. 25. – P. 309–340.
14. Morimoto R., Satoh F., Murakami O. et al.
Immunohistochemistry of a proliferation marker Ki67/MIB1 in
adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor
for recurrence of adrenocortical carcinomas. Endocrine Journal. –
2008. – Vol. 55. – P. 49–55.
15. Park B.K., Kim C.K., Kim B. et al. Comparison of delayed
enhanced CT and chemical shift MR for evaluating hyperattenuating
incidental adrenal masses. Radiology. – 2007. – Vol. 243. – P.
760–765.
16. Samnotra V., Vassilopoulou-Sellin R & Fojo AT. A phase
II trial of gefitinib monotherapy in patients with unresectable
adrenocortical carcinoma (ACC). Proceedings of the Annual
Meeting of the American Society of Clinical Oncology. – 2007
[abstract no 15527].
17. Sasano H., Suzuki T. & Moriya T. Recent advances
in histopathology and immunohistochemistry of adrenocortical
carcinoma. Endocrine Pathology. – 2006. – Vol. 17. – P. 345–354.
18. Schlamp A., Hallfeldt K., Mueller-Lisse U. et al. Recurrent
adrenocortical carcinoma after laparoscopic resection. Nature
Clinical Practice, Endocrinology & Metabolism. – 2007. – Vol. 3.
– P. 191–195. quiz 1 p following 195.
19. Schteingart D.E., Doherty G.M., Gauger P.G. et al.
Management of patients with adrenal cancer: recommendations
of an international consensus conference. Endocr Relat Cancer. –
2005. – Vol. 12. – P. 667–680.
20. Song J.H., Chaudhry F.S. & Mayo-Smith W.W. The
incidental adrenal mass on CT: prevalence of adrenal disease
in 1,049 consecutive adrenal masses in patients with no known
malignancy. AJR American Journal of Roentgenology. – 2008. –
Vol. 190. – P. 1163–1168.
21. Terzolo M., Angeli A., Fassnacht M. et al. Adjuvant mitotane
treatment in patients with adrenocortical carcinoma. The New
England Journal of Medicine. – 2007. – Vol. 356. – P. 372–380.
22. Quinkler M., Hahner S., Wortmann S. et al. Treatment of
advanced adrenocortical carcinoma with erlotinib plus gemcitabine.
The Journal of Clinical Endocrinology and Metabolism. – 2008. –
Vol. 93. – P. 2057–2062.